United Therapeutics (NASDAQ:UTHR) Given New $625.00 Price Target at Cantor Fitzgerald

United Therapeutics (NASDAQ:UTHR) had its price objective lifted by Cantor Fitzgerald from $525.00 to $625.00 in a research note published on Thursday morning, MarketBeat.com reports. Cantor Fitzgerald currently has an overweight rating on the biotechnology company’s stock.

UTHR has been the subject of a number of other research reports. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. TD Cowen boosted their price target on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, HC Wainwright boosted their target price on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $548.09.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $532.82 on Thursday. The firm’s 50-day moving average price is $485.89 and its 200-day moving average price is $458.53. The company has a market capitalization of $23.35 billion, a PE ratio of 19.10, a P/E/G ratio of 1.96 and a beta of 0.84. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $548.12.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same period last year, the company posted $6.19 EPS. United Therapeutics’s revenue was up 7.4% on a year-over-year basis. Equities analysts anticipate that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 338,947 shares of company stock worth $165,516,573. 10.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Geneos Wealth Management Inc. raised its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Atria Investments Inc lifted its holdings in shares of United Therapeutics by 12.6% during the 2nd quarter. Atria Investments Inc now owns 945 shares of the biotechnology company’s stock valued at $272,000 after buying an additional 106 shares during the period. AE Wealth Management LLC boosted its stake in shares of United Therapeutics by 7.6% in the 2nd quarter. AE Wealth Management LLC now owns 864 shares of the biotechnology company’s stock worth $248,000 after buying an additional 61 shares during the last quarter. Aviva PLC grew its holdings in shares of United Therapeutics by 1,688.4% in the second quarter. Aviva PLC now owns 33,122 shares of the biotechnology company’s stock worth $9,518,000 after acquiring an additional 31,270 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of United Therapeutics by 15.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 36,977 shares of the biotechnology company’s stock worth $10,625,000 after acquiring an additional 4,824 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.